Luna Innovations Incorporated (NASDAQ: LUNA), a company focusing on sensing & instrumentation and pharmaceutical nanomedicines, today announced its financial results for the third quarter ended September 30, 2008.
Kent Murphy, Chairman and Chief Executive Officer, provided this overview of Luna’s results:
“I am pleased to report that during the third quarter we continued to achieve our planned improvement in both revenue and bottom line results. For the first time, we achieved quarterly revenue in excess of $10 million. Our revenues of $10.7 million in the third quarter of 2008 represent an increase of 21% as compared to the same quarter last year, with growth of more than 20% in both of our lines of business. Our gross profit increased from $3.5 million in the third quarter of 2007 to $4.3 million this past quarter, and due in part to our continued focus on our operating expenses, our loss per share declined from $0.18 to $0.04. Excluding a one-time benefit that we realized on a litigation settlement with our former auditors, our net loss per share would have been $0.10, which is a substantial improvement compared to the third quarter of 2007.
“Our higher-margin product and license revenues continue to grow, and we remain on track to achieve a growth of approximately 30% in that segment this year as compared to last year. We also had continued success in strengthening our Technology Development Division and have a solid backlog of contracts specifically supporting much of our product development efforts.
“Also during the past quarter, we announced a National Institutes of Health grant from the National Cancer Institute to develop a contrast agent that is targeted to image brain cancers. Under this program, Luna is tasked with producing an improved magnetic resonance imaging (MRI) agent to enhance tumor imaging and advance the diagnosis and treatment of this disease by directing nanomolecules to specific biological targets. We expect that our exclusive nanotechnology using carbon nanospheres can meet the needs of this program.”
Third Quarter Financial Highlights
-- Achieved quarterly revenue greater than $10 million. Total revenues for the third quarter of 2008 increased 21% compared to the third quarter of 2007.
-- Product and license revenues grew 21% to approximately $3.5 million in the third quarter of 2008, compared to $2.9 million in the third quarter of 2007.
-- Gross profit for the third quarter of 2008 increased 21% to $4.3 million from $3.5 million for the corresponding period of 2007.
-- Operating expenses decreased 3% to $5.4 million, or 50% of total revenues, from $5.5 million, or 63% of total revenues, in the third quarter of 2007.
-- Net loss improved to $0.5 million from $1.8 million in the third quarter of 2007. Excluding the one-time benefit from a July 2008 settlement of a dispute with our former auditing firm the net loss would have been $1.1 million.
-- Net loss per share for the third quarter of 2008 was $0.04 per share. Excluding the non-recurring, non-operating income related to the July 2008 settlement, net loss per share for the third quarter of 2008 would have been $0.10 per share compared to a net loss per share of $0.18 in the third quarter of 2007.
-- Cash and cash equivalents totaled $15.2 million at September 30, 2008, as compared to $15.3 million at June 30, 2008, and $12.0 million at December 31, 2007.
Third Quarter Business Highlights
-- Awarded a grant from the National Cancer Institute to adapt Luna’s exclusive carbon nanosphere-based contrast agent technology to produce an improved MRI agent for enhanced tumor imaging and advanced diagnosis and treatment.
-- Continued to meet the development objectives and timeline of our partnership with Intuitive Surgical, Inc. to adapt Luna’s shape sensing technology for use in medical robotics for minimally invasive surgery.
-- Demonstrated an increase in the number of hair follicles and growth of new hair on a second species of mouse using a topical application of our proprietary nanomedical compound; identified the lead compound for future development efforts of this potential product.
-- Realized 20% increase in organic solar cell overall efficiency based upon the increase in open circuit voltage obtained from using Luna’s exclusive TRIMETASPHERE® in place of the empty cage fullerenes typically used today.
Outlook for Remainder of 2008
For the fourth quarter of 2008, the company currently anticipates continued year-over-year growth in both its product and license segment and its Technology Development Division. The company currently expects total revenue to be in the range of $40.0 million to $41.0 million for 2008. Also for 2008, the company anticipates a net loss in the range of $6.0 million to $6.5 million. The improvement in expected net loss for the year from our earlier guidance of $6.5 million to $7.0 million reflects the non-recurring benefit realized from the July 2008 settlement. Accordingly, for the fourth quarter of 2008, the company expects revenue of approximately $10.5 million to $11.5 million and a net loss of approximately $1.8 million to $2.3 million. The higher expected loss in the fourth quarter of 2008 compared to the current quarter is primarily attributable to the expected increase in costs related to on-going litigation with Hansen Medical as Luna progresses toward trial in that matter.
Conference Call Information
As previously announced, Luna Innovations will conduct an investor conference call at 11:00 a.m. (EST) today to discuss its financial results, business developments and expectations for 2008. The call can be accessed by dialing 1.866.202.1971 domestically or 1.617.213.8842 internationally prior to the start of the call. The access code is 48200647. The conference call will also be webcast live over the Internet. The webcast can be accessed by logging on to the “Investor Relations” section of the Luna Innovations Web site, http://www.lunainnovations.com, prior to the event. The webcast will be archived under the “Webcasts and Presentations” section of the Luna Innovations Web site for at least 30 days following the conference call.
About Luna Innovations:
Luna Innovations Incorporated (www.lunainnovations.com) develops and manufactures new-generation products for the healthcare, telecommunications, energy and defense markets. Our products are used to measure, monitor, protect and improve critical processes in the markets we serve. Through its disciplined commercialization business model, Luna has become a recognized leader in transitioning science to solutions. Luna is headquartered in Roanoke, Virginia.
Forward Looking Statements:
This release includes information that constitutes “forward-looking statements” made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding, but not limited to: (i) the company’s ability to successfully develop an improved magnetic resonance imaging, or MRI, contrast agent pursuant to its grant from the National Cancer Institute, (ii) the company’s ability to successfully obtain regulatory approval and to sell an improved MRI contrast agent, (iii) the company’s anticipated growth in its product and license and technology development divisions in 2008 and increased revenues in those areas, (iv) the company’s continued success and profitability from its partnership with Intuitive Surgical, Inc., (v) the company’s expectations regarding future products and revenues that may be generated from its research in new technologies, including hair growth and solar cell applications of its nanotechnology, (vi) the company’s expectations with respect to the resolution of litigation with Hansen Medical; and (vii) the company’s financial outlook for its fourth quarter 2008 and full fiscal year 2008, including expected revenues and net loss as well as the underlying growth rates assumptions and expected components thereof. The company attempts, whenever possible, to identify forward-looking statements by words such as “intends,” “will,”“plans,” “anticipates,”“expects,” “may,”“estimates,” “believes,”“should,” “projects,” or “continue,” or the negative of those words and other comparable words. Similarly, statements that describe the company’s business strategy, goals, prospects, opportunities, outlook, objectives, plans or intentions are also forward-looking statements. Actual events or results may differ materially from the expectations expressed in such forward-looking statements as a result of various factors, including risks and uncertainties, many of which are beyond the company’s control. Factors that could cause actual results to differ materially from the expectations expressed in such forward-looking statements include, but are not limited to: the company’s ability to manage its growth effectively; the company’s ability to transition its revenue mix to product revenues and the company’s limited experience in manufacturing products on a commercial scale; the company’s ability to successfully identify market needs for new products; the company’s ability to attract skilled employees; the company’s continued reliance on contract research, including government grants and contracts available only to small businesses, for a significant portion of its revenue; the company’s ability to remain eligible for small business government grants and contracts in the future; the company’s ability to maintain sufficient proprietary rights to protect its technologies; the potential adverse effects of nanotechnology, whether real or perceived; the potential limitations of regulatory requirements in obtaining clearance by the U.S. Food and Drug Administration or other regulatory agencies for the company’s products; and risks inherent in current or future litigation proceedings. Additional factors that may affect the future results of the company are set forth in the company’s quarterly and annual reports on Form 10-Q and Form 10-K, respectively, and other filings with the Securities and Exchange Commission (“SEC”), which are available at the SEC’s website at http://www.sec.gov, and at the company’s website at http://www.lunainnovations.com. These risk factors are updated from time to time through the filing of periodic reports with the SEC. The statements made in this press release are based on information available to the company as of the date of this release and Luna Innovations undertakes no obligation to update any of the forward-looking statements herein after the date of this press release.
Luna Innovations Incorporated Consolidated Statements of Operations
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Contract research revenues||$||7,246,674||$||5,952,747||$||20,795,697||$||17,091,452|
|Product and license revenues||3,456,872||2,867,453||8,706,075||6,654,200|
|Cost of revenues:|
|Contract research costs||4,983,336||4,008,829||13,558,984||11,929,264|
|Product and license costs||1,453,467||1,281,367||4,222,699||2,670,916|
|Total cost of revenues||6,436,803||5,290,196||17,781,683||14,600,180|
|Other income (expense)|
|Interest income, net||(36,323||)||93,690||(45,345||)||290,571|
|Total other income||630,802||143,205||621,780||338,475|
|Loss before income taxes||(473,985||)||(1,838,352||)||(4,124,430||)||(6,698,221||)|
|Income tax expense||-||-||-||-|
|Net loss per share:|
|Weighted average shares:|
Luna Innovations Incorporated Consolidated Balance Sheets
|September 30,||December 31,|
|Cash and cash equivalents||$||15,181,265||$||12,046,945|
|Accounts receivable, net||10,415,251||9,716,610|
|Refundable income taxes||390,661||396,062|
|Other current assets||533,484||333,105|
|Total current assets||28,812,629||24,167,961|
|Property and equipment, net||5,639,168||5,859,515|
|Intangible assets, net||1,815,895||1,911,132|
|Deferred tax asset||600,000||600,000|
|Liabilities and stockholders' equity|
|Current portion of capital lease obligation||$||21,458||$||23,885|
|Current portion of long-term debt obligation||1,071,429||-|
|Total current liabilities||12,305,317||10,053,056|
|Long-term capital lease obligation||-||4,671|
|Long-term debt obligation||8,928,571||5,000,000|
|Deferred credits and other long term liabilities||-||354,418|
Preferred stock, par value $0.001, 5,000,000 shares authorized, no shares issued and outstanding
Common stock, par value $0.001, 100,000,000 shares authorized, 11,102,365 and 10,704,456 shares issued and outstanding
|Additional paid-in capital||37,244,157||34,496,063|
|Total stockholders' equity||15,760,795||17,136,733|
|Total liabilities and stockholders' equity||$||36,994,683||$||32,548,878|
Luna Innovations Incorporated Consolidated Statements of Cash Flows
|Nine months ended|
|Cash flows used in operating activities|
Adjustments to reconcile net loss to net cash used in operating activities:
|Depreciation and amortization||1,425,857||1,324,155|
|Change in assets and liabilities:|
|Accounts payable and accrued expenses||1,493,982||1,071,451|
|Net cash used in operating activities||(1,317,555||)||(3,779,103||)|
|Cash flows used in investing activities|
|Acquisition of property and equipment||(318,436||)||(1,233,932||)|
|Intangible property costs||(378,780||)||(320,110||)|
|Net cash used in investing activities||(697,216||)||(1,554,042||)|
|Cash flows from financing activities|
|Proceeds from/ (Payments on) debt obligations||5,000,000||(214,955||)|
|Payments on capital lease obligations||(7,098||)||(63,036||)|
|Proceeds from the exercise of options and warrants||156,189||272,777|
|Net cash used in financing activities||5,149,091||(5,214||)|
|Net change in cash||3,134,320||(5,338,359||)|
|Cash - beginning of period||12,046,945||17,866,753|
|Cash - end of period||$||15,181,265||$||12,528,394|
Luna Innovations Incorporated Reconciliation of Net Loss and
Loss Per Share
|Net loss, as reported||$||(473,985||)|
Deduct net benefit realized from litigation settlement proceeds
|Net loss, before litigation settlement||$||(1,140,317||)|
|Net loss per share before litigation settlement:|
|Weighted average shares:|